Regnier-Rosencher E - Search Results

1

Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors.

Almebayadh M, Regnier-Rosencher E, Carlotti A, Goulvestre C, Le Guern V, Mouthon L, Avril MF, Dupin N. Almebayadh M, et al. Among authors: regnier rosencher e. Dermatology. 2013;226(2):119-23. doi: 10.1159/000346694. Epub 2013 Mar 23. Dermatology. 2013. PMID: 23548825

2

Treatments for classic Kaposi sarcoma: a systematic review of the literature.

Régnier-Rosencher E, Guillot B, Dupin N. Régnier-Rosencher E, et al. J Am Acad Dermatol. 2013 Feb;68(2):313-31. doi: 10.1016/j.jaad.2012.04.018. Epub 2012 Jun 12. J Am Acad Dermatol. 2013. PMID: 22695100 Review.

3

Age and clear eyes are associated with an increased risk of cutaneous squamous cell carcinomas in vemurafenib-treated melanoma patients.

Herms F, Kramkimel N, Regnier-Rosencher E, Carlotti A, Chanal J, Boitier F, Aractingi S, Dupin N, Avril MF. Herms F, et al. Among authors: regnier rosencher e. Melanoma Res. 2016 Oct;26(5):487-91. doi: 10.1097/CMR.0000000000000275. Melanoma Res. 2016. PMID: 27261949

4

Factors associated with severe skin infections in patients treated with biologic therapies for inflammatory rheumatic diseases.

Régnier-Rosencher E, Farhi D, Lebrun A, Salliot C, Dougados M, Dupin N. Régnier-Rosencher E, et al. Dermatology. 2012;224(1):72-83. doi: 10.1159/000337422. Epub 2012 Apr 6. Dermatology. 2012. PMID: 22487697

5

Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.

Regnier-Rosencher E, Lazareth H, Gressier L, Avril MF, Thervet E, Dupin N. Regnier-Rosencher E, et al. Br J Dermatol. 2013 Oct;169(4):934-8. doi: 10.1111/bjd.12555. Br J Dermatol. 2013. PMID: 23909652

6

Late occurrence of Histoplasma duboisii cutaneous and pulmonary infection 18 years after exposure.

Régnier-Rosencher E, Dupont B, Jacobelli S, Paugam A, Carlotti A, Boitier F, Gorin I, Dupin N, Avril MF. Régnier-Rosencher E, et al. J Mycol Med. 2014 Sep;24(3):229-33. doi: 10.1016/j.mycmed.2014.08.001. Epub 2014 Aug 23. J Mycol Med. 2014. PMID: 25155354

7

Do anti-hypertensive renin-angiotensin system inhibitors contribute to the development of classical Kaposi sarcoma?

Régnier-Rosencher E, Boutron I, Avril MF, Dupin N. Régnier-Rosencher E, et al. J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1199-201. doi: 10.1111/jdv.13120. Epub 2015 Apr 6. J Eur Acad Dermatol Venereol. 2016. PMID: 25851266 No abstract available.

8

First-line treatment with paclitaxel for non-HIV-related Kaposi sarcoma: experience in 10 cases.

Denis D, Régnier-Rosencher E, Kramkimel N, Jafari A, Avril MF, Dupin N. Denis D, et al. Among authors: regnier rosencher e. Br J Dermatol. 2016 Apr;174(4):905-8. doi: 10.1111/bjd.14237. Epub 2016 Jan 6. Br J Dermatol. 2016. PMID: 26479548 No abstract available.

9

A fifth subtype of Kaposi's sarcoma, classic Kaposi's sarcoma in men who have sex with men: a cohort study in Paris.

Denis D, Seta V, Regnier-Rosencher E, Kramkimel N, Chanal J, Avril MF, Dupin N. Denis D, et al. Among authors: regnier rosencher e. J Eur Acad Dermatol Venereol. 2018 Aug;32(8):1377-1384. doi: 10.1111/jdv.14831. Epub 2018 Feb 14. J Eur Acad Dermatol Venereol. 2018. PMID: 29377280

10

BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients.

Vanhaecke C, Deilhes F, Chanal J, Regnier-Rosencher E, Boitier F, Boulinguez S, Avril MF, Guégan S, Dupin N, Aractingi S, Meyer N, Kramkimel N. Vanhaecke C, et al. Among authors: regnier rosencher e. Br J Dermatol. 2017 Oct;177(4):e94-e95. doi: 10.1111/bjd.15345. Epub 2017 Aug 30. Br J Dermatol. 2017. PMID: 28129668 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters